Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.

DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial

StockBot

416,823 posts

MSB released this announcement to the ASX on 11 November 2020, 10:11. The announcement is marked as price sensitive, and is 3 page(s) in length and 117.63kb in size.

You can view all announcements from MSB and see how they appear on a price chart on the announcements page.

At the date of this announcement, MSB was 9.018% short sold according to ASIC data. It was ranked the 6th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).

Other Recent Announcements from MSB
Change of Director's Interest Notice 13 June 2023, 8:56
Mesoblast Director Appointed to Strategic Advisory Role 5 June 2023, 9:41
MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023, 8:32
DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial 11 November 2020, 10:11
COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C 29 October 2020, 10:05
Annual Report to shareholders 26 October 2020, 15:15
Notice of Annual General Meeting and Proxy Form 26 October 2020, 15:03
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track MSB and receive email alerts.